Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153797 · ClinicalTrials.gov registry record · NA
A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors
A NA study of Hematologic Malignancy and Caregiver, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06153797: Active NA study of Hematologic Malignancy and Caregiver, sponsored by Brigham and Women's Hospital.
NCT06153797 is a NA study of Hematologic Malignancy and Caregiver that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 80 participants, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06153797, a NA study of Hematologic Malignancy and Caregiver, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this randomized clinical trial is to evaluate whether a positive psychology intervention (PATH-C) can improve psychological well-being, quality of life, and physical activity in caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT).
Primary Outcome
PATH-C Intervention Feasibility is defined as \>60% of eligible participants enrolling in the study and \>60% of enrolled participants who start the intervention completing at least 6/9 intervention sessions.
Conditions Studied
Interventions
- BEHAVIORAL PATH-C
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2027-01-31 |
| Phase | NA |
What the registry record for NCT06153797 still lists
NCT06153797 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which PATH-C is the first listed.
NCT06153797 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06153797 about?
NCT06153797 is a clinical study titled "A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors". The goal of this randomized clinical trial is to evaluate whether a positive psychology intervention (PATH-C) can improve psychological well-being, quality of life, and physical activity in caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT).
What is the current status of trial NCT06153797?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-01-01. Estimated completion is 2027-01-31.
What conditions does trial NCT06153797 study?
This clinical trial studies the following conditions: Hematologic Malignancy, Caregiver.
What interventions are being tested in trial NCT06153797?
The interventions under investigation include: PATH-C (BEHAVIORAL).
Who is sponsoring clinical trial NCT06153797?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06153797 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06153797's enrollment target sits among peer trials
80 16th of 48 higher than 32 of 48 other Hematologic Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Implementation of an Oral Chemotherapy Adherence Intervention
RECRUITING · NA
-
ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
RECRUITING · NA
-
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
RECRUITING · NA
-
Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI